返回 
加入收藏
西妥昔单抗联合NP方案同期放化疗用于晚期非小细胞肺癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 西妥昔单抗联合NP方案同期放化疗用于晚期非小细胞肺癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨西妥昔单抗联合NP方案同期放化疗用于晚期非小细胞肺癌（NSCLC）的临床疗效及安全性。方法：选取晚期NSCLC患者76例，依据治疗方法的不同分为对照组和观察组，各38例。对照组患者给予NP方案（顺铂25 mg/m2 +长春瑞滨12.5 mg/m2）化疗+胸腔调强放疗；观察组患者在对照组基础上加用西妥昔单抗400 mg/m2（第1天），每周维持剂量250 mg/m2，持续13周。比较两组患者的近期临床疗效、生存情况及治疗前后T淋巴细胞亚群、辅助性T细胞（Th）1、Th2、免疫球蛋白（Ig）及补体水平，并记录不良反应发生情况。结果：观察组患者总有效率为86.84％，显著高于对照组的65.79％，差异有统计学意义（P＜0.05）。观察组患者的平均生存时间为18.70个月，2年生存率为55.26％，显著长于/高于对照组的14.75个月和31.58％，差异均有统计学意义（P＜0.05）。观察组患者生存质量稳定提高率为94.74％，显著高于对照组的68.42％，差异有统计学意义（P＜0.05）。治疗后，两组患者CD4+、CD4+/CD8+和IgG的水平明显增高，CD8+、补体C3、Th1、Th2及Th1/Th2显著下降，且观察组显著优于对照组，差异均有统计学意义（P＜0.05）；两组患者CD3+、IgA、IgM及补体C4水平比较，差异无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：西妥昔单抗联合NP方案同期放化疗能显著提高晚期NSCLC患者的临床疗效，改善生存质量，延长生存时间，促进Ig、补体和T淋巴细胞水平的恢复，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To explore the clinical efficacy and safety of cetuximab combined with NP regimen and radiotherapy in the treatment of advanced non-small cell lung cancer（NSCLC）. METHODS： 76 cases of advanced NSCLC were selected and randomly divided into control group and observation group according to different therapy methods， with 38 cases in each group. Control group received NP regimen （cisplatin 25 mg/m2 + navelbine 12.5 mg/m2）+thoracic IMRT； observation group was additionally given cetuximab 400 mg/m2 （first day）， with maintenance dose of 250 mg/m2 weekly and last for 13 weeks. Short-term efficacy， survival situation were compared between 2 groups as well as the levels of T lymphocyte， Th1， Th2， immuneglobulin（Ig） and complement. The occurrence of ADR was recorded. RESULTS： The total effective rate of observation group was 86.84％， which was significantly higher than that of control group （65.79％）， with statistical significance （P＜0.05）. Average survival period and 2-year survival rate of observation group were 18.70 months and 55.26％， which were significantly longer or higher than those of control group （14.75 months， 31.58％）， with statistical significance （P＜0.05）. The improvement rate of survival quality was 94.74％ in observation group， which was significantly higher than 68.42％ in control group， with statistical significance （P＜0.05）. After treatment， the levels of CD4+， CD4+/CD8+ and IgG were significantly increased in 2 groups， while the levels of CD8+， Th1， Th2 and Th1/Th2 were significantly decreased； the observation group was better than the control group， with statistical significance （P＜0.05）； there was no statistical significance in the levels of CD3+， IgA， IgM and complement 4 between 2 groups （P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Cetuximab combined with NP regimen and radiotherapy can improve clinical efficacy of advanced NSCLC， improve survival quality， prolong survival time and promote the recovery of Ig， complement and T lymphocyte， with good safety. |
| 期刊： | 2016年第27卷第26期 |
| 作者： | 陈类吉，谢羽婕，陈昌洪，张弛，张智慧 |
| AUTHORS： | CHEN Leiji，XIE Yujie，CHEN Changhong，ZHANG Chi，ZHANG Zhihui |
| 关键字： | 非小细胞肺癌；西妥昔单抗；免疫球蛋白；补体；T淋巴细胞；NP方案 |
| KEYWORDS： | Non-small cell lung cancer； Cetuximab； Immunoglobulin； Complement； T lymphocyte； NP Regimen |
| 阅读数： | 264 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
